

# Joel W Neal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8674590/publications.pdf>

Version: 2024-02-01

88  
papers

7,831  
citations

147726

31  
h-index

54882

84  
g-index

88  
all docs

88  
docs citations

88  
times ranked

11039  
citing authors

#	ARTICLE	IF	CITATIONS
1	EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, e148-e153.	1.1	16
2	Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 264-272.	1.1	11
3	Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. <i>Clinical Lung Cancer</i> , 2022, 23, e210-e221.	1.1	11
4	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100497.	0.7	4
5	Abstract PO-130: Disparities in risk of second primary lung cancer among lung cancer patients in the United States. , 2022, , .		0
6	Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 295-306.	1.3	16
7	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	1.3	4
8	The Survival Impact of Second Primary Lung Cancer in Patients With Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 618-625.	3.0	13
9	Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 649-662.	4.9	15
10	Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens. <i>Clinical Lung Cancer</i> , 2022, 23, 498-509.	1.1	1
11	EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9146-TPS9146.	0.8	3
12	PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review. <i>Clinical Lung Cancer</i> , 2021, 22, e329-e335.	1.1	4
13	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	4.2	40
14	Opportunistic Invasive Fungal Infections Mimicking Progression of Non-small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e193-e200.	1.1	12
15	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 534-542.	1.5	14
16	Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. <i>Cancer Discovery</i> , 2021, 11, 1688-1699.	7.7	154
17	Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2021, 3, 137-139.	1.7	55
18	Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. <i>Immunity</i> , 2021, 54, 586-602.e8.	6.6	80

#	ARTICLE	IF	CITATIONS
19	Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. <i>JCO Oncology Practice</i> , 2021, 17, e1688-e1697.	1.4	7
20	Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. <i>Clinical Lung Cancer</i> , 2021, 22, 201-209.	1.1	24
21	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 868-872.	0.5	42
22	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	0.5	79
23	Radiological tumour classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021, 3, 787-798.	8.3	41
24	Relative Impact of Anticancer Therapy on Unplanned Hospital Care in Patients With Nonâ€“Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e1131-e1138.	1.4	1
25	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2029-2039.	0.5	34
26	The role of ramucirumab with docetaxel in epidermal growth factor receptor mutant and wild-type non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 4864-4871.	0.6	3
27	Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1479-1489.	0.5	2
28	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of <i>KRAS</i> -Mutated Nonâ€“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 153-162.	1.5	4
29	Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1994-1998.	0.5	7
30	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	3.2	75
31	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
32	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
33	A PHASE IIA STUDY REPOSITIONING DESIPRAMINE IN SMALL CELL LUNG CANCER AND OTHER HIGH-GRADE NEUROENDOCRINE TUMORS. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100174.	0.7	10
34	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	13.7	379
35	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	5.7	201
36	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74

#	ARTICLE	IF	CITATIONS
37	Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9610-9610.	0.8	25
38	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019, 133, 144-150.	0.9	90
39	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 42-45.	0.9	37
40	Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor-Induced Pneumonitis. <i>Journal of Thoracic Oncology</i> , 2019, 14, e75-e77.	0.5	2
41	Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption. <i>JAMA Dermatology</i> , 2019, 155, 848.	2.0	4
42	<i>EGFR</i>-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. <i>Journal of Clinical Oncology</i> , 2019, 37, 278-285.	0.8	286
43	Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes", <i>Lung Cancer</i> , 2019, 137, 159-160.	0.9	2
44	Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e21-e24.	0.5	23
45	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e208-e217.	1.1	9
46	Osimertinib for <i>EGFR</i>-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective Study. <i>Oncologist</i> , 2019, 24, 836-843.	1.9	34
47	Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. <i>Clinical Cancer Research</i> , 2018, 24, 2771-2779.	3.2	141
48	Infiltrating the Blood-Brain Barrier in ALK-Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2677-2679.	0.8	8
49	Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	3
50	<i>EGFR</i> Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an <i>EGFR</i> Tyrosine Kinase Inhibitor. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	8
51	Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e581-e588.	1.1	22
52	Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations. <i>Lung Cancer</i> , 2018, 122, 187-191.	0.9	5
53	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
54	ERBB2 -Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 833-842.	0.5	86

#	ARTICLE	IF	CITATIONS
55	Elusive Target of Angiogenesis in Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1269-1271.	0.8	5
56	The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer. <i>Cancer</i> , 2017, 123, 2798-2801.	2.0	2
57	Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 431-436.	1.6	2
58	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 125, 338-343.	0.3	29
59	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	7.7	701
60	Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 16-21.	0.4	14
61	Novel systemic therapy against malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2017, 6, 295-314.	1.3	22
62	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, e8-e15.	1.8	13
63	Concordant and Discordant EGFR Mutations in Patients With Multifocal Adenocarcinomas: Implications for EGFR-Targeted Therapy. <i>Clinical Therapeutics</i> , 2016, 38, 1567-1576.	1.1	11
64	Molecular profiling of single circulating tumor cells from lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E8379-E8386.	3.3	90
65	Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. <i>Journal of Oncology Practice</i> , 2016, 12, 763-764.	2.5	1
66	Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1661-1671.	5.1	115
67	Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. <i>Nature Communications</i> , 2016, 7, 11815.	5.8	520
68	Integrated digital error suppression for improved detection of circulating tumor DNA. <i>Nature Biotechnology</i> , 2016, 34, 547-555.	9.4	837
69	Unicentric, Multifocal Castleman Disease of the Mediastinum Associated With Cerebellitis. <i>Annals of Thoracic Surgery</i> , 2015, 99, e7-e9.	0.7	5
70	Developing biomarker-specific end points in lung cancer clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 135-146.	12.5	43
71	Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1547-1552.	3.3	115
72	Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy. <i>American Journal of Ophthalmology</i> , 2015, 160, 799-805.e1.	1.7	68

#	ARTICLE	IF	CITATIONS
73	Dovitinib and erlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. <i>Lung Cancer</i> , 2015, 89, 280-286.	0.9	18
74	Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects. <i>Lung Cancer</i> , 2015, 90, 1-7.	0.9	14
75	Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 366-373.	1.1	23
76	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015, 87, 34-38.	0.9	27
77	Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers. <i>Translational Lung Cancer Research</i> , 2015, 4, 639-41.	1.3	16
78	GLI1, CTNNB1 and NOTCH1 protein expression in a thymic epithelial malignancy tissue microarray. <i>Anticancer Research</i> , 2015, 35, 669-76.	0.5	5
79	An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. <i>Nature Medicine</i> , 2014, 20, 548-554.	15.2	1,771
80	Successes, toxicities and challenges in solid tumours. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 627-628.	12.5	23
81	Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. <i>Clinical Lung Cancer</i> , 2014, 15, 202-206.	1.1	68
82	Review of the current targeted therapies for non-small-cell lung cancer. <i>World Journal of Clinical Oncology</i> , 2014, 5, 576.	0.9	59
83	A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. <i>Clinical Lung Cancer</i> , 2013, 14, 592-595.	1.1	33
84	A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors. <i>Cancer Discovery</i> , 2013, 3, 1364-1377.	7.7	366
85	Aflibercept in lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 115-120.	1.4	6
86	Current Management of Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2011, 32, 853-863.	0.8	34
87	Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. <i>Current Treatment Options in Oncology</i> , 2010, 11, 36-44.	1.3	48
88	The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. <i>Future Oncology</i> , 2010, 6, 1827-1832.	1.1	19